ABILIFY MAINTENA, 2,567 patients have been treated with ABILIFY MAINTENA 400 mg/300 and significantly lower relapse rates with ABILIFY
(ABILIFY MAINTENA) (300 mg and 400 mg vial) CDR submission: PrAbilify Maintena aripiprazole prolonged release suspension for injection 300 mg.
ABILIFY MAINTENA, , OTSUKA PHARMACEUTICAL CO LTD, ARIPIPRAZOLE 300 MG / SYR. Previous1Next ABILIFY MAINTENA. ARIPIPRAZOLE 300 MG / VIAL. ABILIFY
ABILIFY MAINTENA, , OTSUKA PHARMACEUTICAL CO LTD, ARIPIPRAZOLE 300 MG / SYR. Previous1Next ABILIFY MAINTENA. ARIPIPRAZOLE 300 MG / VIAL. ABILIFY
ABILIFY MAINTENA injections of 300 mg to 400 mg. ABILIFY MAINTENA 300 mg powder and solvent for prolonged-release suspension for injection aripiprazole.
Company: OTSUKA PHARMACEUTICAL CO LTD ; , ABILIFY MAINTENA, ARIPIPRAZOLE, 300 MG / VIAL, KIT ; , ABILIFY MAINTENA, ARIPIPRAZOLE, 300 MG / VIAL
Each vial of ABILIFY MAINTENA 300 MG contains aripiprazole 300 mg (as Monohydrate). Each vial of ABILIFY MAINTENA 400 MG contains aripiprazole 400 mg (as
ID. altLabel. ARIPiprazole 300 MG Injection [Abilify]. Abilify Maintena 300 MG Injection.
between ABILIFY MAINTENA and placebo: 6.4% for the ABILIFY MAINTENA 400 mg/300 mg group and 5.2% for the placebo group. The incidence of
Comments